Human Patents (Class 424/142.1)
-
Patent number: 8841424Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: GrantFiled: May 11, 2010Date of Patent: September 23, 2014Assignee: U3 Pharma GmbHInventors: Peter Wirtz, Jens Ruhe, Takeshi Takizawa, Tomoko Takayama
-
Publication number: 20140271653Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Anne Gurnett-Bander, David Perez-Caballero, Sumathi Sivapalasingam, Xunbao Duan, Douglas MacDonald
-
Publication number: 20140271658Abstract: The present invention provides antibodies that bind to interleukin-33 (IL-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate IL-33-mediated signaling. The antibodies of the invention may function to block the interaction between IL-33 and ST2. Alternatively, certain antibodies of the invention inhibit or attenuate IL-33-mediated signaling without blocking the IL-33/ST2 interaction. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human IL-33 with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as inflammatory diseases, or allergic diseases.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Andrew J. Murphy, Nicholas J. Papadopoulos, Jamie M. Orengo
-
Patent number: 8834871Abstract: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.Type: GrantFiled: March 27, 2012Date of Patent: September 16, 2014Assignee: The Board of the University of Texas SystemInventor: E. Sally Ward Ober
-
Publication number: 20140255388Abstract: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments, and methods of making and using the foregoing are disclosed.Type: ApplicationFiled: March 13, 2013Publication date: September 11, 2014Inventors: Jill M. Carton, Shizhong Chen, Mark Cunningham, Anuk Das, Karen Duffy, Jill Giles-Komar, Theresa Goletz, David Knight, Roberta Lamb, Lamine Mbow, Gopalan Raghunathan, Lani San Mateo, Robert Sarisky, Nicole Stowell, Raymond Sweet, Shanrong Zhao
-
Publication number: 20140255404Abstract: The disclosure relates to agents that inhibit the activity of osteoprotegerin and their use in the treatment of pulmonary hypertension.Type: ApplicationFiled: October 23, 2012Publication date: September 11, 2014Applicant: PH TherapeuticsInventor: Allan Lawrie
-
Publication number: 20140255393Abstract: Methods and compositions are described for categorizing and treating autoimmune disease, using single cell network profiling (SCNP), where activation levels of one or more activatable elements are determined in single cells, with or without modulation, to categorize or determine treatment for the autoimmune disease.Type: ApplicationFiled: February 28, 2014Publication date: September 11, 2014Applicant: Nodality, Inc.Inventors: Jason Ptacek, Rachael Hawtin, Erik Evensen, James Cordeiro, Alessandra Cesano
-
Publication number: 20140255419Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia.Type: ApplicationFiled: May 23, 2014Publication date: September 11, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Joyce Harp, Haruka Okamoto
-
Patent number: 8828391Abstract: The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.Type: GrantFiled: May 15, 2012Date of Patent: September 9, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Louis Denis, Robert Michael Lorence, Mehdi Shahidi, Flavio Solca
-
Patent number: 8828390Abstract: The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus.Type: GrantFiled: July 8, 2011Date of Patent: September 9, 2014Assignees: Universitat Zurich, Universite de GeneveInventors: Pedro L. Herrera, Martin E. Schwab, Claire Bonal, Patrice Lalive D'epinay, Caroline Pot Kreis
-
Patent number: 8828998Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).Type: GrantFiled: March 15, 2013Date of Patent: September 9, 2014Assignee: Infinity Pharmaceuticals, Inc.Inventors: Vito J. Palombella, David G. Winkler
-
Publication number: 20140248277Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: ApplicationFiled: March 28, 2014Publication date: September 4, 2014Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Phillip Yan
-
Publication number: 20140248275Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: ApplicationFiled: March 28, 2014Publication date: September 4, 2014Applicant: ABBVIE BIOTECHNOLOGY LTD.Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Phillip Yan
-
Publication number: 20140248270Abstract: A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder, the composition including a wax and a therapeutically effective amount of tar for topical treatment of the tar-responsive dermatological disorder, the composition being in liquid form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Inventors: Ruey J. YU, Eugene J. VAN SCOTT
-
Publication number: 20140248215Abstract: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of psoriatic arthritis in a subject.Type: ApplicationFiled: August 26, 2013Publication date: September 4, 2014Inventors: Rebecca S. Hoffman, Eric H. Sasso, Renee J. Perdok, Philip Yan, Mark Weinberg, Phillip Mease, Christopher T. Ritchlin, Dafna D. Gladman
-
Publication number: 20140248276Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: ApplicationFiled: March 28, 2014Publication date: September 4, 2014Applicant: ABBVIE BIOTECHNOLOGY LTD.Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Phillip Yan
-
Publication number: 20140248211Abstract: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.Type: ApplicationFiled: May 16, 2014Publication date: September 4, 2014Applicant: INTENSITY THERAPEUTICS, INC.Inventor: Lewis H. Bender
-
Patent number: 8822645Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: July 8, 2009Date of Patent: September 2, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Jijie Gu, Peter C. Isakson
-
Publication number: 20140242072Abstract: The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for ICAM-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods for the administration of such antibodies, fragments, variants, fusion and derivatives thereof.Type: ApplicationFiled: September 27, 2012Publication date: August 28, 2014Applicant: BIOINVENT INTERNATIONAL ABInventor: Markus Hansson
-
Publication number: 20140234328Abstract: The present invention relates to use of the human Met receptor (also known as “c-Met”) for predicting the efficacy of inhibitors of the HGF-Met pathway, and in particular, anti-HGF antibodies, in the treatment of esophageal and gastric cancer patients. The present invention also relates to methods and kits for predicting the usefulness of anti-HGF antibodies in the treatment of esophageal and gastric cancer.Type: ApplicationFiled: September 7, 2012Publication date: August 21, 2014Applicant: AMGEN INC.Inventors: Abraham Anderson, Kelly Oliner, Rui Tang, Elwyn Loh, Sarita Dubey
-
Publication number: 20140234222Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.Type: ApplicationFiled: March 28, 2014Publication date: August 21, 2014Applicant: AbbVie Biotechnology, Ltd.Inventors: Rebecca S. Hoffman, Mark Weinberg
-
Publication number: 20140234314Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
-
Patent number: 8809562Abstract: Metallocene compounds and pharmaceutical compositions containing these metallocene compounds are disclosed and described. Methods of treating cancer employing such metallocene compounds and pharmaceutical compositions also are provided.Type: GrantFiled: June 5, 2012Date of Patent: August 19, 2014Assignee: Chevron Phillips Chemical Company LPInventors: Mark L. Hlavinka, Qing Yang, Mandi Michelle Murph
-
Patent number: 8802103Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.Type: GrantFiled: May 15, 2008Date of Patent: August 12, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
-
Publication number: 20140220014Abstract: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease.Type: ApplicationFiled: February 28, 2014Publication date: August 7, 2014Applicants: University of Washington, ZymoGenetics, Inc.Inventors: Stacey R. Dillon, Jane A. Gross, Keith B. Elkon
-
Publication number: 20140220133Abstract: A composition and methods to bind and remove toxic agents from a subject exposed to the toxic agents are described herein. The composition comprises a stealth agent and scavenging agent bound to a nanoparticle platform. The stealth agent prevents the nanomedicine from detection and elimination by the immune system allowing the scavenging agent to bind the target toxic agent. The stealth agent comprises an exposing group that once removed from the stealth agent allows the nanomedicine and bound toxic agent to be detected and eliminated from the subject's body.Type: ApplicationFiled: November 27, 2013Publication date: August 7, 2014Inventors: Giulio F. Paciotti, Lawrence Tamarkin
-
Publication number: 20140220013Abstract: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.Type: ApplicationFiled: October 21, 2013Publication date: August 7, 2014Applicant: University of Louisville Research Foundation, Inc.Inventors: Paula J. Bates, Donald M. Miller, John Q. Trent, Xiaohua Xu
-
Patent number: 8795665Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to human BMP-6, compositions comprising such antibodies, or antigen-binding fragments thereof, and methods of using the same for treatment of anemia of chronic disease.Type: GrantFiled: December 5, 2013Date of Patent: August 5, 2014Assignee: Eli Lilly and CompanyInventors: Neungseon Seo, Stephanie Marie Eaton Truhlar
-
Publication number: 20140212430Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Phillip Yan
-
Patent number: 8790648Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.Type: GrantFiled: May 15, 2012Date of Patent: July 29, 2014Assignee: Amgen Inc.Inventors: Joel Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
-
Publication number: 20140205609Abstract: Pharmaceutical compositions comprising molecules produced by antigen-stimulated peripheral blood mononuclear cells (PBMCs) that induce systemic immune responses to cancers are encompassed herein, as are methods for making and administering such molecules and pharmaceutical compositions comprising same. Also encompassed herein are mixtures of molecules produced by antigen-stimulated PBMCs and compositions thereof for use in treating cancer. Methods for stimulating a systemic immune response in a subject afflicted with a cancer are also envisioned, whereby molecules produced by antigen-stimulated PBMCs or supernatants comprising same are administered to the subject, wherein the molecules stimulate an immune response to the cancer in the subject.Type: ApplicationFiled: January 23, 2014Publication date: July 24, 2014Inventor: Fred T. Valentine
-
Patent number: 8785599Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than the antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also provides the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: June 26, 2007Date of Patent: July 22, 2014Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang, Robyn Gerena
-
Patent number: 8784809Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: January 24, 2013Date of Patent: July 22, 2014Assignee: Human Genome Sciences, Inc.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Patent number: 8784811Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: GrantFiled: February 22, 2013Date of Patent: July 22, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
-
Patent number: 8784815Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.Type: GrantFiled: November 1, 2012Date of Patent: July 22, 2014Assignee: Medarex, L.L.C.Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
-
Publication number: 20140199320Abstract: The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of IL-1?, IL-1 receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of IL-1?, IL-1 receptor type 1, IL-1 receptor type 2, NLRP3, ASC and Caspase-1. Similarly, an interfering RNA or an antisense modulator of gene expression of IL-1?, I L-1? receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B are provided for the prevention or treatment of acne.Type: ApplicationFiled: July 11, 2012Publication date: July 17, 2014Applicant: UNIVERSITAT ZURICHInventors: Dragana Jankovic, Magdalena Kistowiska, Emmanuel Contassot, Lars E. French, Samuel Gehrke
-
Publication number: 20140199299Abstract: This invention relates generally to compositions that contain multiple modulating agents, e.g., multiple modulating agents that target CD3 on T cells and neutralize one or more biological activities of interleukin-6 (IL-6), such as CD3 modulators including anti-CD3 antibodies and anti-IL-6 antagonists including anti-IL-6 antibodies, anti-IL-6R antagonists including anti-IL-6R antibodies, and/or anti-IL-6/IL-6R complex antagonists including anti-IL-6/IL-6R binding antibodies, and methods of using these compositions in the treatment, amelioration and/or prevention of relapse of an autoimmune disease.Type: ApplicationFiled: March 20, 2014Publication date: July 17, 2014Inventors: Yann Dean, Fabien Depis
-
Publication number: 20140199236Abstract: Described herein is the androgen receptor modulator of formula (I) in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.Type: ApplicationFiled: January 9, 2014Publication date: July 17, 2014Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: ISAN CHEN, JEFFREY H. HAGER, EDNA CHOW MANEVAL, MARK R. HERBERT, NICHOLAS D. SMITH
-
Patent number: 8778339Abstract: The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with CD20 expression that encompass administration of a combination of: (A) one or more antibodies that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies bind Fc?RIIA, and (B) one or more antibodies that specifically bind to CD20. Such methods include methods of treating, preventing, managing or ameliorating one or more symptoms of a B cell related disease or disorder or an inflammatory disorder. The invention also provides pharmaceutical compositions comprising an anti-Fc?RIIB antibody and an anti-CD20 antibody.Type: GrantFiled: December 23, 2008Date of Patent: July 15, 2014Assignee: MacroGenics, Inc.Inventors: Nadine Tuaillon, Christopher Rankin
-
Publication number: 20140193413Abstract: The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.Type: ApplicationFiled: August 8, 2012Publication date: July 10, 2014Applicants: DYAX CORP., ATHERA BIOTECHNOLOGIES ABInventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
-
Publication number: 20140193422Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.Type: ApplicationFiled: March 14, 2014Publication date: July 10, 2014Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
-
Patent number: 8771695Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.Type: GrantFiled: April 15, 2010Date of Patent: July 8, 2014Assignees: U3 Pharma GmbH, Amgen, Inc.Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges
-
Patent number: 8771697Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: GrantFiled: June 8, 2012Date of Patent: July 8, 2014Assignee: Novimmune SAInventors: Krzysztof Masternak, Olivier Leger
-
Patent number: 8771696Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia.Type: GrantFiled: May 22, 2013Date of Patent: July 8, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Joyce Harp, Haruka Okamoto
-
Publication number: 20140186363Abstract: The present invention relates to MAGEA3 binding antibodies.Type: ApplicationFiled: May 23, 2012Publication date: July 3, 2014Applicants: UNIVERSITY OF ZURICH, CT ATLANTIC LTD.Inventors: Christoph Esslinger, Michael Höcker, Martin Treder, Alexander Knuth, Elke Jaeger
-
Publication number: 20140186362Abstract: The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFN?), thereby modulating the interaction between IFN? and its receptor, IFN?-R, and/or modulating the biological activities of IFN?. The invention also relates to the use of such anti-IFN? antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder.Type: ApplicationFiled: October 18, 2013Publication date: July 3, 2014Inventors: Walter Ferlin, Nicolas Fischer, Greg Elson, Olivier Leger
-
Publication number: 20140186264Abstract: Extracellular vesicle-associated protein biomarkers for use in diagnosing and staging carcinomas, e.g., lung and ovarian cancers.Type: ApplicationFiled: March 12, 2013Publication date: July 3, 2014Applicant: University of Louisville Research Foundation, Inc.Inventor: University of Louisville Research Foundation, Inc.
-
Publication number: 20140186446Abstract: Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 ?m.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Inventors: Mikael Trollsas, John Stankus, James Su, Syed Hossainy, Joshua Takeshi Smith, Shadid Askar
-
Publication number: 20140186361Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: ApplicationFiled: September 6, 2013Publication date: July 3, 2014Applicant: Coherus Biosciences, Inc.Inventors: Mark Manning, Robert W. Payne
-
Publication number: 20140178295Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: Janssen Biotech, Inc.Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy